SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.415-6.4%3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: End2War who wrote (1195)10/21/2025 7:09:02 PM
From: waitwatchwander1 Recommendation

Recommended By
CCS648

  Read Replies (2) of 1216
 
Our goal now to treat cancer earlier in the disease or even treat patients before they get cancer. We are proud to say that the trial with NCI in Lynch syndrome (cancer free patients with a 80 percent higher risk of getting cancer) is now fully recruited… a cancer prevention trial.

This sounds really good especially the "earlier" part.

I'm surprised this whole approach has yet the be tested within mice. Surely, they can promote NK and T cells within such an environment and subsequently introduce cancer cells.

Maybe I'm just too neophyte to understand the complexity.

ps Increasing the authorized share count by 25%, not so great. PSS et al must be see a need for speed and great expenditure of additional funding before anything here takes hold.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News